Amplexd Therapeutics, Inc., a biotech company focused on accessible treatments for HPV-induced Cervical Intraepithelial Neoplasia (CIN), has announced significant progress in its product development. The company has secured $2 million in funding from an Asia-based life sciences focused family office to advance its non-invasive treatments for CIN, the precursor to cervical cancer.
CEO Alia Rahman expressed excitement about the funding, stating that it marks a major milestone in their R&D efforts after promising preclinical studies. This capital will enable them to finalize development and submit for IND ahead of Phase 1/2 clinical trials expected to start later this year.
Amplexd Therapeutics aims to provide two topical, non-invasive treatment options for CIN, offering alternatives to the current “watch and wait” approach for low-grade CIN and invasive surgery for high-grade CIN. These therapies are designed to prioritize patient comfort and increase access to treatment, addressing the public health crisis of HPV-induced cervical precancers.
Founded in 2022, Amplexd Therapeutics has been making waves in the women’s health space with its innovative approach to CIN treatment. The company’s mission is to provide accessible solutions for the millions of women globally affected by CIN, a condition that can lead to invasive cancer if left untreated.
Rahman’s personal experience with chronic CIN inspired the development of Amplexd Therapeutics. After undergoing invasive surgery for high-grade CIN, Rahman embarked on a journey to create non-invasive therapies using green tea polyphenols. These treatments have the potential to revolutionize CIN care by offering a more comfortable and accessible alternative to surgery.
With the support of this recent funding, Amplexd Therapeutics is poised to make a significant impact in the field of HPV and cervical precancer treatments, providing hope for improved outcomes for women worldwide.